NewAmsterdam Pharma Co N.V (NAMS) Debt to Equity: 2022-2025
Historic Debt to Equity for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $0.06.
- NewAmsterdam Pharma Co N.V's Debt to Equity rose 22.13% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.06, marking a year-over-year increase of 22.13%. This contributed to the annual value of $0.05 for FY2024, which is 13.59% up from last year.
- Latest data reveals that NewAmsterdam Pharma Co N.V reported Debt to Equity of $0.06 as of Q3 2025, which was up 126.61% from $0.03 recorded in Q2 2025.
- Over the past 5 years, NewAmsterdam Pharma Co N.V's Debt to Equity peaked at $0.08 during Q1 2024, and registered a low of $0.01 during Q4 2022.
- Its 3-year average for Debt to Equity is $0.05, with a median of $0.05 in 2024.
- As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Debt to Equity skyrocketed by 352.16% in 2023, and later tumbled by 62.31% in 2025.
- Over the past 4 years, NewAmsterdam Pharma Co N.V's Debt to Equity (Quarterly) stood at $0.01 in 2022, then skyrocketed by 352.16% to $0.04 in 2023, then increased by 13.59% to $0.05 in 2024, then climbed by 22.13% to $0.06 in 2025.
- Its Debt to Equity was $0.06 in Q3 2025, compared to $0.03 in Q2 2025 and $0.03 in Q1 2025.